Streetbeat News

Analyst Ratings

ANET

META

Arista Networks (ANET) has shown strong growth in 2Q23, driven by a surge in enterprise demand. Analysts from Keybanc, Needham, JMP Securities, and Morgan Stanley have maintained positive ratings and raised their price targets for ANET. The company's growth is attributed to its expanding opportunities with Cloud Titans, CSPs, and Enterprise, including AI-related expansion. However, one of its significant customers, believed to be Meta Platforms (META), reduced capex spending, slowing cloud titan deployments.

Portfolio Pulse from Anusuya Lahiri

August 04, 2023 | 10:22 am

CVS

A significant bullish stance has been taken on CVS Health (NYSE:CVS) by a large investor, as indicated by unusual options trading activity. The sentiment among these big-money traders is 71% bullish and 28% bearish. The targeted price range for CVS Health over the last 3 months is from $35.0 to $90.0. Analysts from JP Morgan, Barclays, and Mizuho have maintained their positive ratings on CVS Health, with price targets of $106, $89, and $88 respectively.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:22 am

ANDE

Andersons (NASDAQ:ANDE) reported Q2 earnings of $1.52 per share, beating the analyst consensus estimate of $1.06 by 43.4%. However, this is a 35.59% decrease from the same period last year. The company's quarterly sales of $4.02 billion missed the analyst consensus estimate of $4.15 billion by 3.20%, marking a 9.68% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:21 am

SEDG

SolarEdge Technologies reported Q2 adjusted earnings of $2.62 per share, beating the analyst consensus estimate of $2.55 by 2.75%. This is a 175.79% increase from the same period last year. The company also reported quarterly sales of $991.30 million, beating the analyst consensus estimate of $989.17 million by 0.22%. This is a 36.21% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:19 am

RIGL

Rigel Pharmaceuticals reported Q2 earnings per share of $(0.04), beating the analyst consensus estimate of $(0.08) by 50%. The company also reported quarterly sales of $26.89 million, beating the analyst consensus estimate of $26.02 million by 3.33%. However, this represents a 9.84% decrease in sales compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 04, 2023 | 10:19 am

INSP

Inspire Medical Systems (NYSE:INSP) reported Q2 losses of $(0.41) per share, beating the analyst consensus estimate of $(0.51) by 19.61%. The company also reported quarterly sales of $151.09 million, beating the analyst consensus estimate of $137.66 million by 9.76%. This represents a 22.64% increase in losses and a 65.33% increase in sales compared to the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 04, 2023 | 10:19 am

VICI

Analysts have provided ratings for VICI Props (NYSE:VICI) in the last quarter, with 3 somewhat bullish, 2 indifferent, and none bearish. The average price target is $36.6, implying an upside from the current price of $31.64. This average has increased by 0.74% from the previous average price target of $36.33.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:16 am

TRNS

Analysts have provided bullish ratings for Transcat (NASDAQ:TRNS) in the last quarter, with 5 bullish and 1 somewhat bullish ratings. The average 12-month price target for Transcat has increased by 7.15% to $102.33 from the previous target of $95.50.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:16 am

MRVL

A significant bearish stance has been taken on Marvell Tech (NASDAQ:MRVL) by a large investor, as indicated by unusual options activity. The overall sentiment of these big-money traders is split between 42% bullish and 57% bearish. The price of MRVL is up 1.31% at $65.98. Barclays, Keybanc, and Stifel have maintained their positive ratings on Marvell Tech with price targets of $75 and $80, while Wolfe Research downgraded its action to Outperform with a price target of $80.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:15 am

AMP

Analysts have provided ratings for Ameriprise Finl (NYSE:AMP) in the last quarter, with 1 somewhat bullish and 3 indifferent. The company has an average 12-month price target of $362.5, an increase of 1.9% from the previous average price target of $355.75.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:15 am